Osteoarthritis of the hip
Conditions
Interventions
subcutaneous injection denosumab, 60mg every 6 months use for 2 years
oral risedronate, 17.5mg once weekly, use for 2 years
Sponsors
Shonan Kamakura Joint Reconstruction Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Osteoarthritis of the hip 2) Young Adult Mean< 80% / Proximal femur or Lumbar vertebra
Exclusion criteria
Exclusion criteria: 1) oral Bisphosphonate therapy for more than 3 years 2) oral Bisphosphonate therapy within 6 months prior to the study enrollment 3) oral Bisphosphonate therapy for more than 2 weeks between 6 months and 3 years prior to the study enrollment 4) intravenous Bisphosphonate therapy within 5 years prior to the study enrollment 5) Parathyroid hormone therapy within 6 weeks prior to the study enrollment 6) A history of Osteotomy 7) sever renal dysfunction (GFR< 30) 8) sever liver dysfunction 9) malignant tumor 10) hypocalcemia, hypokalemia 11) A history ofesophagostenosis, esophageal achalasia 12) A history of hyperparathyroidism 13) glucocorticoids therapy 14) pregnant woman 15) The patients should be excluded, who have poor medical compliance, drug-induced allergy, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage change in periprosthetic bone mineral density | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in bone mineral density of the vertebra, The percentage change in bone metabolic markers of resorption and formation, Harris Hip Score, Periprosthetic X-ray change | — |
Countries
Japan
Contacts
Public ContactNariaki Nakura
Shonan Kamakura Joint Reconstruction Center Department of Orthopedic
Outcome results
None listed